ALLARITY THERAPEUTICS INC(NASDAQ:ALLR) stock Fundamental Analysis

Fundamental Rating

Overall ALLR gets a fundamental rating of 2 out of 10. We evaluated ALLR against 568 industry peers in the Biotechnology industry. While ALLR seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLR is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALLR had negative earnings in the past year.

ALLR had a negative operating cash flow in the past year.

In the past 5 years ALLR always reported negative net income.

In the past 5 years ALLR always reported negative operating cash flow.

1.2 Ratios

ALLR has a worse Return On Assets (-95.31%) than 75.00% of its industry peers.

The Return On Equity of ALLR (-149.82%) is worse than 63.03% of its industry peers.

		Industry Rank	Sector Rank
ROA	-95.31%
ROE	-149.82%
ROIC	N/A

ROA(3y)-123.51%

ROA(5y)-87.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ALLR has been increased compared to 1 year ago.

ALLR has a better debt/assets ratio than last year.

2.2 Solvency

ALLR has an Altman-Z score of -7.98. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -7.98, ALLR is doing worse than 69.89% of the companies in the same industry.

ALLR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.98

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.75 indicates that ALLR has no problem at all paying its short term obligations.

With a Current ratio value of 2.75, ALLR is not doing good in the industry: 68.31% of the companies in the same industry are doing better.

ALLR has a Quick Ratio of 2.75. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.

ALLR's Quick ratio of 2.75 is on the low side compared to the rest of the industry. ALLR is outperformed by 66.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.75
Quick Ratio	2.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.71% over the past year.

EPS 1Y (TTM)99.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.43%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ALLR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y99.94%

EPS Next 2Y41.41%

EPS Next 3Y25.98%

EPS Next 5Y18.92%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALLR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALLR's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.41%

EPS Next 3Y25.98%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALLR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (4/23/2025, 7:37:55 PM)

After market: 1.01 0 (0%)

1.01

+0.02 (+1.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners2.36%

Inst Owner Change0%

Ins Owners16.8%

Ins Owner Change71.58%

Market Cap17.18M

Analysts43.33

Price TargetN/A

Short Float %17.79%

Short Ratio0.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)36.85%

Min EPS beat(2)11.28%

Max EPS beat(2)62.42%

EPS beat(4)2

Avg EPS beat(4)-282.05%

Min EPS beat(4)-1133.29%

Max EPS beat(4)62.42%

EPS beat(8)5

Avg EPS beat(8)-136.82%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.33
P/tB	1.33
EV/EBITDA	N/A

EPS(TTM)-933.21

EYN/A

EPS(NY)-47.86

Fwd EYN/A

FCF(TTM)-0.93

FCFYN/A

OCF(TTM)-0.93

OCFYN/A

SpS0

BVpS0.76

TBVpS0.76

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-95.31%
ROE	-149.82%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-123.51%

ROA(5y)-87.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.75
Quick Ratio	2.75
Altman-Z	-7.98

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)99.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.43%

EPS Next Y99.94%

EPS Next 2Y41.41%

EPS Next 3Y25.98%

EPS Next 5Y18.92%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y2.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y15.37%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y15.37%

OCF growth 3YN/A

OCF growth 5YN/A

ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens